Androgenetic Alopecia (Pattern Hair Loss) Treatment in Cuba

Understanding Androgenetic Alopecia

Androgenetic alopecia — commonly known as male or female pattern baldness — is the most common type of hair loss, affecting approximately 50% of men by age 50 and a significant proportion of women. Unlike alopecia areata (autoimmune) or telogen effluvium (stress-triggered), androgenetic alopecia is a progressive, genetically determined condition caused by the sensitivity of hair follicles to the hormone dihydrotestosterone (DHT).

In men, androgenetic alopecia typically presents as a receding hairline forming an 'M' shape, followed by thinning at the crown, eventually progressing to baldness over the top of the scalp. In women, the pattern is different — diffuse thinning over the entire top of the scalp with widening of the part, while the frontal hairline is usually maintained. Women rarely develop complete baldness.

The key biological process in androgenetic alopecia is follicle miniaturization. Under the influence of DHT, affected hair follicles gradually shrink with each hair growth cycle. The anagen (growth) phase shortens, the hairs produced become finer and shorter, and eventually the follicles produce only invisible vellus hairs. This process occurs over years to decades.

Understanding this mechanism is important for treatment — early intervention, while follicles are still producing visible (though thinning) hairs, offers the best chance of meaningful results. Once follicles have completely miniaturized and stopped producing visible hairs, stimulating regrowth becomes much more difficult.

The Role of DHT & Genetic Sensitivity

Dihydrotestosterone (DHT) is a hormone derived from testosterone through the action of the enzyme 5-alpha-reductase. DHT is more potent than testosterone and plays a role in male development, but it also causes hair follicles in genetically predisposed individuals to miniaturize.

Key points about the DHT mechanism: • Not everyone with high DHT loses hair — hair loss depends on genetic sensitivity of follicles to DHT, not just DHT levels. Some people have high DHT but no hair loss because their follicles are not sensitive. • Follicle sensitivity varies by location — Follicles on the top and front of the scalp are genetically programmed to be sensitive to DHT, while follicles on the back and sides of the scalp are not (which is why hair transplants use donor hair from the back). • Progressive miniaturization — Each hair cycle produces a finer, shorter hair until the follicle produces only vellus (peach fuzz) hairs. • Genetic inheritance — The genetic predisposition can be inherited from either or both parents. Contrary to the old myth, it is not solely inherited from the mother's side.

This understanding guides treatment approaches. Conventional treatments target this mechanism: finasteride blocks 5-alpha-reductase to reduce DHT production, while minoxidil stimulates follicles through vasodilation. Cuba's Piloactive offers an alternative pathway — stimulating follicles through multiple growth factors without hormonal manipulation.

Piloactive for Androgenetic Alopecia

Piloactive offers a non-hormonal approach to androgenetic alopecia treatment. Rather than blocking DHT (like finasteride) or causing vasodilation (like minoxidil), Piloactive delivers placental growth factors that:

• Stimulate follicle cell proliferation — EGF and FGF in the extract stimulate the keratinocytes and dermal papilla cells of the hair follicle, promoting active hair production even in miniaturizing follicles. • Prolong the anagen phase — By keeping follicles in the growth phase longer, Piloactive helps counteract the DHT-induced shortening of the growth phase that causes miniaturization. • Improve follicle nutrition — Enhanced scalp circulation delivers more oxygen and nutrients to follicles, supporting healthier hair production. • Support follicle recovery — Growth factors may help partially reverse the miniaturization process, encouraging follicles to produce thicker, longer hairs again.

Piloactive is particularly valuable for patients who: • Cannot or prefer not to use finasteride (women, men concerned about potential side effects) • Have not responded adequately to minoxidil • Seek a biological, non-hormonal approach • Want to complement their existing treatment regimen

For patients already using finasteride or minoxidil, Piloactive can be used as a complementary therapy — the different mechanisms may provide additive benefit. Cuba's dermatologists evaluate each case and design an individualized treatment plan that may combine Piloactive with conventional treatments when appropriate.

Expected Results & Long-Term Management

Androgenetic alopecia is a progressive, lifelong condition. No treatment — including Piloactive — permanently cures it. Treatment goals are realistic:

• Reduce the rate of hair loss — Slowing progression is often the most achievable goal, particularly in advanced cases. • Stimulate regrowth in thinning areas — Follicles that are still producing visible (though thinning) hairs have the best potential for regrowth. Completely bald areas where follicles have fully miniaturized are less likely to respond. • Improve hair density and quality — Existing hairs may become thicker and stronger, improving overall appearance even without dramatic regrowth.

Timeline for results: • 4-8 weeks — Reduction in shedding may be noticed. Hair in the anagen phase becomes stronger. • 3-6 months — Visible improvement in hair density in thinning areas. New hairs may begin to appear. • 6-12 months — Peak results from the initial treatment course, with continued maintenance needed to sustain benefits.

Because androgenetic alopecia is progressive, ongoing treatment is needed to maintain results. After the initial in-clinic treatment in Cuba, patients continue with a take-home Piloactive protocol. Periodic follow-up (via telemedicine or return visits) allows the care team to assess progress and adjust the protocol.

It is important to have realistic expectations. Cuba's dermatologists provide an honest assessment during the initial evaluation, indicating the likely outcomes based on the stage of hair loss, the areas affected, and the individual's overall health.